![Ulrike Gnad-Vogt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ulrike Gnad-Vogt
Directeur Technique/Scientifique/R&D chez
CureVac SE
Profil
Ulrike Gnad-Vogt is currently the Chief Medical Officer at CureVac SE since 2011.
Previously, she worked as the Chief Development Officer, SVP & Head-Oncology at CureVac NV from 2022 to 2023.
Dr. Gnad-Vogt obtained a doctorate degree from Universität des Saarlandes.
Postes actifs de Ulrike Gnad-Vogt
| Sociétés | Poste | Début |
|---|---|---|
CureVac SE
 CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Anciens postes connus de Ulrike Gnad-Vogt
| Sociétés | Poste | Fin |
|---|---|---|
| CUREVAC | Directeur Technique/Scientifique/R&D | 01/01/2019 |
Formation de Ulrike Gnad-Vogt
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
19
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Health Technology |
Universität des Saarlandes
 Universität des Saarlandes Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CureVac NV
 CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies | Health Technology |
